|
시장보고서
상품코드
1452461
숙주 세포 단백질 검사 시장 예측(-2032년)Host Cell Protein Testing Market Research Report Forecast till 2032 |
||||||
숙주 세포 단백질 검사 시장 규모는 예측 기간 동안 5.73%의 연평균 복합 성장률(CAGR)로 견조한 성장을 나타낼 것으로 예측되고 있습니다. R&D의 진전 및 바이오의약품 사업의 진보가 사업 부문의 발전을 촉진하고 있습니다.
숙주 세포 단백질 검사 시장은 생물학적 제제 및 바이오시밀러에 대한 관심의 확대, 감염의 일반화, 기술 혁신의 수용 등의 요인에 의해 예측 기간 동안 큰 성장을 나타낼 것으로 예측되고 있습니다. 시장의 중심 기업은 새로운 체제를 육성하기 위해 R&D에 자원을 투입하고 있습니다.
이 보고서는 세계의 숙주 세포 단백질 검사 시장을 조사했으며,, 시장 정의 및 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모 추이 및 예측, 각종 구분, 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.
목차
제1장 주요 요약
제2장 시장 개요
제3장 조사 방법
제4장 시장 역학
- 개요
- 성장 촉진요인
- 바이오의약품 산업의 발전
- 성장하는 R&D 활동
- 억제요인
- 검사 키트의 효율 및 정밀도에 관한 문제
- 기회
- 기술의 진보
제5장 시장 요인 분석
- 밸류체인 분석
- Porter's Five Forces 모델
- COVID-19의 영향
- 실행 샘플 총수 : 기술 유형별
- 지역 및 국가별 규제 상황 분석
제6장 세계의 숙주 세포 단백질 검사 시장 : 유형별
- 개요
- PCR 기반 분석
- ELISA 기반 분석
- 질량 분석 기반 분석
- 기타
제7장 세계의 숙주 세포 단백질 검사 시장 : 최종 사용자별
- 개요
- CRO
- 바이오의약품 기업
- 기타
제8장 세계의 숙주 세포 단백질 검사 시장 : 지역별
- 개요
- 북미
- 유럽
- 아시아태평양
- 기타 지역
제9장 경쟁 구도
- 개요
- 시장 점유율 분석
- 경쟁의 대시보드
- 일반 기업의 주식 개요
- 비교 분석 : 주요 기업의 재무 상황
- 주요 전개 및 성장 전략
제10장 기업 프로파일
- ENZO LIFE SCIENCES, INC
- BIO-RAD LABORATORIES, INC
- BIOGENES GMBH
- CISBIO BIOASSAYS
- ABCAM PLC
- THERMO FISHER SCIENTIFIC INC
- CYTIVA
- CYGNUS TECHNOLOGIES, LLC
- ROCKLAND IMMUNOCHEMICALS, INC
- AGILENT TECHNOLOGIES, INC
제11장 데이터 인용
AJY 24.04.09Market Overview
Host Cell Protein Testing Market is estimated to register a healthy CAGR of 5.73% during the review period. The developing Research and development exercises and advancements in the biopharmaceutical business are driving business sector development.
The host Cell Protein testing market is supposed to observe hearty development during the conjecture time frame, driven by elements, for example, expanding interest for biologics and biosimilars, developing commonness of ongoing infections, and reception of trend setting innovations for HCP testing. Also, central parts in the market are putting resources into Research and development exercises to foster new arrangements, as most would consider to be normal to additional fuel the market development.
The rise of constant and viral illnesses all over the planet has expanded use on Research and development drives. The medication improvement process is being advanced quickly by mechanical progression and development in biomedical sciences. This headway has sped up the advancement of medications and diminished the medication lifecycle period by 500 days. Also, instructive establishments and exploration associations are putting resources into the development of melded and useful proteins. The rising interests in drug solidness have expanded the interest for better host cell protein strategies. In addition, Researchers are exploring techniques to keep antibodies and proteins stable in natural conditions.
Moreover, the developing interest for protein-based antibodies to treat viral, bacterial, and other microorganism-based illnesses has energized worldwide exploration endeavors. The rising commonness of sicknesses, for example, paroxysmal nighttime hemoglobinuria and element VII and VIII inadequacy has helped examination into improved restorative and business protein producing. In this manner, during the gauge time frame, such open doors are projected to drive the host cell protein testing market.
Market Segmentation
Based on type, the Host Cell Protein Testing Market is divided into includes mass spectrometry-based assays, PCR-based assays, ELISA-based assays, and others.
The Host Cell Protein Testing Market segmentation is based on end user that include contract research organizations, biopharmaceutical companies, and others.
Regional Insights
The North America host cell protein testing market is likely to lead the host cell protein market in future. This is because of the rising number of clinical preliminaries, rising interest for creative medication for constant sicknesses, and expanding research for quality and cell treatment items in the North American region.
Europe host cell protein testing market represents the second-biggest piece of the pie because of a rising number of clinical preliminaries in nations like Germany, and France, profoundly embraced mechanically progressed items in biopharmaceutical businesses, and agreement research associations. further, Germany host cell protein testing market was credited to hold the biggest piece of the pie, and the France host cell protein testing market is supposed to quickest developing business sector in the European region.
Major Players
The major players in the Host Cell Protein Testing Market include Enzo Life Sciences, Inc (US), Bio-Rad Laboratories, Inc (US), Biogenes GmbH (Germany), Cisbio Bioassays (France), Abcam plc (UK), Thermo Fisher Scientific Inc (US), Cytiva (US), Cygnus Technologies, LLC (US), Rockland Immunochemicals, Inc (US), and Agilent Technologies, Inc (US).
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
- 2.1 DEFINITION
- 2.2 SCOPE OF THE STUDY
- 2.3 RESEARCH OBJECTIVE
- 2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
- 3.1 OVERVIEW
- 3.2 DATA FLOW
- 3.2.1 Data Mining Process
- 3.3 PURCHASED DATABASE:
- 3.4 SECONDARY SOURCES:
- 3.4.1 Secondary Research Data Flow:
- 3.5 PRIMARY RESEARCH:
- 3.5.1 Primary Research DATA FLOW:
- 3.5.2 Primary Research: Number Of Interviews Conducted
- 3.5.3 Primary Research: Regional Coverage
- 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 Revenue Analysis Approach
- 3.7 DATA FORECASTING
- 3.7.1 Data Forecasting Technique
- 3.8 DATA MODELING
- 3.8.1 Microeconomic Factor Analysis:
- 3.8.2 Data Modeling:
- 3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
- 4.1 OVERVIEW
- 4.2 DRIVERS
- 4.2.1 DEVELOPMENTS IN THE BIOPHARMACEUTICAL INDUSTRY
- 4.2.2 Growing R&D Activities
- 4.3 RESTRAINTS
- 4.3.1 Issues Related To The Efficiency And Accuracy Of The Test Kits
- 4.4 OPPORTUNITY
- 4.4.1 Growing Technological Advancements
5 MARKET FACTOR ANALYSIS
- 5.1 VALUE CHAIN ANALYSIS
- 5.1.1 R&D And Designing
- 5.1.2 Manufacturing
- 5.1.3 Distribution & Sales
- 5.1.4 Post-Sales Review
- 5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 Bargaining Power Of Buyers
- 5.2.2 Bargaining Power Of Suppliers
- 5.2.3 Threat Of NEW ENTRANTS
- 5.2.4 THREAT OF SUBSTITUTES
- 5.2.5 Intensity Of Rivalry
- 5.3 IMPACT OF COVID-19
- 5.3.1 Impact On Supply Chain
- 5.3.2 Impact On Production
- 5.3.3 Impact On Demand-Supply Gap Analysis
- 5.4 TOTAL NUMBER OF SAMPLES RUN BY TYPE OF TECHNOLOGY (2022)
- 5.5 ANALYSIS OF REGULATORY LANDSCAPE BY REGION/COUNTRY
- 5.5.1 US
- 5.5.2 EMEA
6 GLOBAL HOST CELL PROTEIN TESTING MARKET, BY TYPE
- 6.1 OVERVIEW
- 6.1.1 PCR-Based Assays
- 6.1.2 ELISA-Based Assays
- 6.1.3 Mass Spectrometry-Based Assays
- 6.1.3.1 Liquid Chromatography-Mass Spectrometry (LC-MS)
- 6.1.3.2 Tandem Mass Spectrometry (MS/MS)
- 6.1.3.3 Others
- 6.1.4 Others
7 GLOBAL HOST CELL PROTEIN TESTING MARKET, BY END USER
- 7.1 OVERVIEW
- 7.1.1 Contract Research Organizations
- 7.1.2 Biopharmaceutical Companies
- 7.1.3 Others
8 GLOBAL HOST CELL PROTEIN TESTING MARKET, BY REGION
- 8.1 OVERVIEW
- 8.2 NORTH AMERICA
- 8.2.1 US
- 8.2.2 CANADA
- 8.3 EUROPE
- 8.3.1 Germany
- 8.3.2 France
- 8.3.3 UK
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest Of Europe
- 8.4 ASIA-PACIFIC
- 8.4.1 CHINA
- 8.4.2 JAPAN
- 8.4.3 INDIA
- 8.4.4 AUSTRALIA
- 8.4.5 SOUTH KOREA
- 8.4.6 REST OF ASIA-PACIFIC
- 8.5 REST OF THE WORLD
- 8.5.1 MIDDLE EAST
- 8.5.2 AFRICA
- 8.5.3 LATIN AMERICA
9 COMPETITIVE LANDSCAPE
- 9.1 OVERVIEW
- 9.2 MARKET SHARE ANALYSIS, 2022
- 9.3 COMPETITOR DASHBOARD
- 9.4 PUBLIC PLAYERS STOCK SUMMARY
- 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
- 9.6 KEY DEVELOPMENTS & GREST OF THE WORLDTH STRATEGIES
- 9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
- 9.6.2 MERGER AND ACQUISITION
- 9.6.3 PARTNERSHIP/INVESTMENT/EXPANSION
10 COMPANY PROFILES
- 10.1 ENZO LIFE SCIENCES, INC
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 KEY DEVELOPMENTS
- 10.1.5 SWOT ANALYSIS
- 10.1.6 KEY STRATEGIES
- 10.2 BIO-RAD LABORATORIES, INC
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 KEY DEVELOPMENTS
- 10.2.5 SWOT ANALYSIS
- 10.2.6 KEY STRATEGIES
- 10.3 BIOGENES GMBH
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 KEY DEVELOPMENTS
- 10.3.5 KEY STRATEGIES
- 10.4 CISBIO BIOASSAYS
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 KEY DEVELOPMENTS
- 10.4.5 KEY STRATEGIES
- 10.5 ABCAM PLC
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 KEY DEVELOPMENTS
- 10.5.5 KEY STRATEGIES
- 10.6 THERMO FISHER SCIENTIFIC INC
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 DISEASE TYPES OFFERed
- 10.6.4 KEY DEVELOPMENTS
- 10.6.5 SWOT ANALYSIS
- 10.6.6 Key Strategy
- 10.7 CYTIVA
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 Products OFFERed
- 10.7.4 KEY DEVELOPMENTS
- 10.7.5 SWOT Analysis
- 10.7.6 KEY STRATEGIES
- 10.8 CYGNUS TECHNOLOGIES, LLC
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 Products OFFERed
- 10.8.4 KEY DEVELOPMENTS
- 10.8.5 Key Strategy
- 10.9 ROCKLAND IMMUNOCHEMICALS, INC
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 DISEASE TYPES OFFERed
- 10.9.4 KEY DEVELOPMENTS
- 10.9.5 KEY STRATEGIES
- 10.10 AGILENT TECHNOLOGIES, INC
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 DISEASE TYPES OFFERed
- 10.10.4 KEY DEVELOPMENTS
- 10.10.5 SWOT ANALYSIS
- 10.10.6 KEY STRATEGIES
